Pfizer Inc. (PFE) said it entered into an agreement with DxS, a wholly owned subsidiary of QIAGEN N.V. (QGEN), to develop a companion diagnostic test kit for PF-04948568, an immunotherapy vaccine in development for the treatment of glioblastoma multiforme. Financial terms of the diagnostic agreement have not been disclosed.
Pfizer's investigational drug PF-04948568 is a peptide vaccine which targets the tumor-specific Epidermal Growth Factor Receptor variant III, a mutated form of the epidermal growth factor receptor that is only present in cancer cells and occurs in 25-40 percent of GBM tumors. The QIAGEN assay is designed to identify those patients whose tumors express the EGFRvIII mutation, allowing for the possibility of more targeted and personalized treatment.
For comments and feedback contact: editorial@rttnews.com
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.